July 3, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Regado Biosciences Inc (NASDAQ:RGDO) shares over potential securities laws violations by Regado Biosciences and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Regado Biosciences Inc (NASDAQ:RGDO) concerning whether a series of statements by Regado Biosciences regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Regado Biosciences Inc reported that its Net Loss increased from $13.06 million in 2012 to $34.44 million in 2013.

Shares of Regado Biosciences Inc (NASDAQ:RGDO) grew from $4.53 per share in September 2013 to as high as $13.50 per share in March 2014.

Then on July 2, 2014 Regado Biosciences Inc, announced, among other things, 'that the Data Safety Monitoring Board, or DSMB, has initiated an unplanned review of data from the Company's Phase 3 trial of Revolixys Kit (previously known as REG1), entitled REGULATE-PCI, and that patient enrollment has been paused in the REGULATE-PCI trial until the DSMB has completed its analysis and communicated its recommendations.'

Shares of Regado Biosciences Inc dropped from $6.99 per share on July 2, 2014, to $2.79 per share during July 3, 2014.